We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Viracta Therapeutics Inc | NASDAQ:VIRX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.0298 | -3.55% | 0.8102 | 0.80 | 0.88 | 0.84 | 0.80 | 0.8212 | 33,087 | 22:16:11 |
From May 2021 to May 2024
By Michael Dabaie
Viracta Therapeutics Inc. shares were up 5% to $9.51 after the company said it reacquired the rights to its combination therapy in China.
The oncology company targeting virus-associated malignancies said it reacquired the exclusive rights to develop and commercialize its all-oral combination product candidate in China previously licensed to Shenzhen Salubris Pharmaceuticals Co. The rights were returned to Viracta in exchange for a $4 million cash payment to Salubris.
Viracta's combination therapy of nanatinostat and valganciclovir is currently in a Phase 2 trial for Epstein-Barr virus-positive lymphoma.
Viracta also received U.S. Food and Drug Administration clearance of an investigational new drug application for a Phase 1b/2 trial of the combination therapy in EBV(+) recurrent or metastatic nasopharyngeal carcinoma and other EBV(+) solid tumors.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
August 23, 2021 11:02 ET (15:02 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Viracta Therapeutics Chart |
1 Month Viracta Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
